solidcolours / iStockphoto.com
US-based Gilead announced Tuesday, September 4 that it has entered into a licensing agreement with biotech company Trianni for an undisclosed sum.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, Trianni, licensing agreement, deal, antibodies, technology, biotech, partnership, Bill Lee, Matthias Wable
